Inclusion Criteria:

          -  All subjects must be >/= 18 years at the first screening examination / visit

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Subjects with advanced, histologically or cytologically confirmed solid tumors
             described to express fibroblast growth factor receptor 2 (FGFR2) that are refractory
             to any standard therapy

          -  For maximum tolerated dose (MTD) Dose Expansion: Subjects with advanced,
             histologically or cytologically confirmed triple-negative breast cancer who had
             undergone within 4 lines of systemic anti-cancer treatment and not eligible for
             standard therapy anymore.

          -  Subjects need to have evaluable disease (measurable or not measurable).

          -  Women of childbearing potential must have a negative pregnancy test performed within 7
             days prior to the start of treatment

        Exclusion Criteria:

          -  History of allergic reactions to monoclonal antibody therapy (or excipients in the
             formulation)

          -  Anti-cancer chemotherapy, experimental cancer therapy including clinical trial, or
             cancer immunotherapy within 4 weeks prior to the first dose of the investigational
             drug.

          -  Toxic effects of previous anti-cancer chemotherapy, experimental cancer therapy, or
             cancer immunotherapy have not normalized.

          -  History of symptomatic metastatic brain or meningeal tumors unless the subject is
             longer than 3 months from the end of definitive therapy before the first dose of the
             investigational drug and has clinically or radiologically no evidence of tumor growth.

          -  History of clinically significant cardiac disease

          -  Congenital coagulation abnormalities

          -  Subjects who are pregnant or are breast-feeding